Do analysts prefer EVFM or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate EVFM or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate CAPS or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend CUPR or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, CUPR or EVFM?

Evofem Biosciences has higher revenue and earnings than Cuprina Holdings (Cayman). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A Evofem Biosciences $11.39M 0.10 $52.98M -$0.07 N/A

Evofem Biosciences (EVFM) Competitors

$0.0082 0.00 (-2.38%)

As of 07/24/2026 02:21 PM Eastern

Compare

EVFM vs. REVB, CELZ, CAPS, SXTP, and CUPR

Should you buy Evofem Biosciences stock or one of its competitors? MarketBeat compares Evofem Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evofem Biosciences include Revelation Biosciences (REVB), Creative Medical Technology (CELZ), Capstone Therapeutics (CAPS), 60 Degrees Pharmaceuticals (SXTP), and Cuprina Holdings (Cayman) (CUPR). These companies are all part of the "pharmaceutical products" industry.

How does Evofem Biosciences compare to Revelation Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evofem Biosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 2 mentions for Evofem Biosciences and 1 mentions for Revelation Biosciences. Evofem Biosciences' average media sentiment score of 0.99 beat Revelation Biosciences' score of 0.94 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Evofem Biosciences	Positive
Revelation Biosciences	Positive

Evofem Biosciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.10	$52.98M	-$0.07	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Revelation Biosciences	N/A	-107.65%	-87.98%

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Evofem Biosciences beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to Creative Medical Technology?

Evofem Biosciences (NASDAQ:EVFM) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Evofem Biosciences has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.10	$52.98M	-$0.07	N/A
Creative Medical Technology	$10K	383.94	-$5.99M	-$2.14	N/A

Creative Medical Technology has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Creative Medical Technology's return on equity of -88.38% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Creative Medical Technology	N/A	-88.38%	-84.71%

Evofem Biosciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evofem Biosciences and Evofem Biosciences both had 2 articles in the media. Creative Medical Technology's average media sentiment score of 1.45 beat Evofem Biosciences' score of 0.99 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Evofem Biosciences	Positive
Creative Medical Technology	Positive

Summary

Creative Medical Technology beats Evofem Biosciences on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Capstone Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

In the previous week, Evofem Biosciences had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Evofem Biosciences and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat Evofem Biosciences' score of 0.99 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Capstone Therapeutics	Very Positive
Evofem Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has lower revenue, but higher earnings than Capstone Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.07	-$21.23M	-$3.37	N/A
Evofem Biosciences	$11.39M	0.10	$52.98M	-$0.07	N/A

Capstone Therapeutics has a net margin of -41.26% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Capstone Therapeutics and Evofem Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Evofem Biosciences had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Evofem Biosciences and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Evofem Biosciences' score of 0.99 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Very Positive
Evofem Biosciences	Positive

Evofem Biosciences has higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A
Evofem Biosciences	$11.39M	0.10	$52.98M	-$0.07	N/A

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Evofem Biosciences has a net margin of -46.42% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Evofem Biosciences on 9 of the 16 factors compared between the two stocks.

How does Evofem Biosciences compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Cuprina Holdings (Cayman) and Cuprina Holdings (Cayman) both had 2 articles in the media. Cuprina Holdings (Cayman)'s average media sentiment score of 1.15 beat Evofem Biosciences' score of 0.99 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Evofem Biosciences	Positive

Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its stock price is 210% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than Cuprina Holdings (Cayman).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A
Evofem Biosciences	$11.39M	0.10	$52.98M	-$0.07	N/A

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Evofem Biosciences	-46.42%	-91.97%	-61.93%

0.2% of Evofem Biosciences shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cuprina Holdings (Cayman) beats Evofem Biosciences on 7 of the 11 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVFM vs. The Competition

Export

Metric	Evofem Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09M	$975.85M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-0.01	1.53	27.11	23.64
Price / Sales	0.10	104.46	517.09	89.57
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.00	8.47	10.28	6.07
Net Income	$52.98M	-$2.70M	$3.60B	$331.99M
7 Day Performance	N/A	-2.29%	-1.27%	-0.63%
1 Month Performance	N/A	-3.97%	-0.37%	-2.00%
1 Year Performance	N/A	27.39%	18.30%	13.62%

Evofem Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVFM Evofem Biosciences	N/A	$0.01 -2.4%	N/A	-15.5%	$1.09M	$11.39M	N/A	120	News Coverage Gap Down
REVB Revelation Biosciences	0.6588 of 5 stars	$1.09 +4.8%	N/A	-91.3%	$4.06M	N/A	N/A	10	High Trading Volume
CELZ Creative Medical Technology	1.5063 of 5 stars	$0.82 -2.4%	N/A	-70.2%	$3.99M	$10K	N/A	5	Positive News Short Interest Decrease
CAPS Capstone Therapeutics	0.7339 of 5 stars	$0.26 +2.4%	N/A	-85.6%	$3.90M	$48.11M	N/A	38	Positive News Gap Up
SXTP 60 Degrees Pharmaceuticals	3.4254 of 5 stars	$1.55 +6.2%	$13.85 +793.5%	-72.4%	$3.88M	$1.41M	N/A	3	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evofem Biosciences (EVFM) Competitors

EVFM vs. REVB, CELZ, CAPS, SXTP, and CUPR

How does Evofem Biosciences compare to Revelation Biosciences?

Summary

How does Evofem Biosciences compare to Creative Medical Technology?

Summary

How does Evofem Biosciences compare to Capstone Therapeutics?

Summary

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

Summary

How does Evofem Biosciences compare to Cuprina Holdings (Cayman)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evofem Biosciences (EVFM) Competitors

EVFM vs. REVB, CELZ, CAPS, SXTP, and CUPR

How does Evofem Biosciences compare to Revelation Biosciences?

Do analysts prefer EVFM or REVB?

Does the media prefer EVFM or REVB?

Which has more risk & volatility, EVFM or REVB?

Which has better valuation & earnings, EVFM or REVB?

Is EVFM or REVB more profitable?

Do institutionals and insiders hold more shares of EVFM or REVB?

Summary

How does Evofem Biosciences compare to Creative Medical Technology?

Which has stronger earnings and valuation, EVFM or CELZ?

Is EVFM or CELZ more profitable?

Which has more volatility and risk, EVFM or CELZ?

Do analysts rate EVFM or CELZ?

Do institutionals and insiders have more ownership in EVFM or CELZ?

Does the media favor EVFM or CELZ?

Summary

How does Evofem Biosciences compare to Capstone Therapeutics?

Do insiders and institutionals hold more shares of CAPS or EVFM?

Which has more risk & volatility, CAPS or EVFM?

Does the media prefer CAPS or EVFM?

Do analysts rate CAPS or EVFM?

Which has preferable earnings & valuation, CAPS or EVFM?

Is CAPS or EVFM more profitable?

Summary

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

Does the media favor SXTP or EVFM?

Which has preferable earnings & valuation, SXTP or EVFM?

Which has more risk and volatility, SXTP or EVFM?

Is SXTP or EVFM more profitable?

Do analysts rate SXTP or EVFM?

Do insiders & institutionals have more ownership in SXTP or EVFM?

Summary

How does Evofem Biosciences compare to Cuprina Holdings (Cayman)?

Does the media refer more to CUPR or EVFM?

Which has more volatility and risk, CUPR or EVFM?

Do analysts recommend CUPR or EVFM?

Which has stronger valuation & earnings, CUPR or EVFM?

Is CUPR or EVFM more profitable?

Do institutionals and insiders have more ownership in CUPR or EVFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools